The New Jersey Alliance for Clinical and Translational Science (NJ ACTS) is committed to advancing clinical and translational science to develop new therapies and treatments and improve health and health care in New Jersey. A consortium coordinated by Rutgers Biomedical and Health Sciences, NJ ACTS includes Rutgers and Princeton Universities, NJ Institute for Technology (NJIT), medical, nursing, dental and public health schools, hospitals, community health centers, outpatient practices, industry, policymakers and health information exchanges. A unique combination of institutions, NJ ACTS is committed to community engagement, ensuring that New Jersyans are partners in our research through patient advocacy and community partnerships.

NJ ACTS supports clinical and translational research, broadly defined, by providing services, expertise, and financial resources; facilitates collaboration among partners; provides training and workforce development; and improves the public’s understanding of science and research.

What is a CTSA?

5 Goals:

• Train and Cultivate Translational Science Workforce
• Engage Patients and Communities
• Integrate Special and Underserved Populations in CTS Across the Lifespan
• Increase the Quality and Efficiency of CTS Research, esp. Multi-site Trials
• Advance the Use of Cutting Edge Informatics

CTSA continuum

What/Who is NJ ACTS?

• Alliance of NJ academic institutions with partners from industry, clinical, state, and community
• Based in the Rutgers Institute for Translational Medicine and Science (RITMS)
• NIH Components:
     – Hub award of 14 Cores (UL1)
     – Institutional Career Development Award (KL2)
     – Institutional Training Award (TL1) Institute for Translational Medicine and Science


$29 Million from NIH – Total of $45 Million Investment